"Notably, they rejected Sarepta’s arguments that Elevidys’ benefits on secondary measures in its main trial make up for the fact its primary outcome was negative. Because that primary statistical test failed, the secondary findings are “misleading” and “cannot guide any stakeholders — including patients, family members and caregivers, and prescribers — in making informed decisions” about Elevidys’ potential benefits, wrote clinical reviewers Mike Singer and Xiaofei Wang.“We cannot reliably distinguish if these results are due to actual effects of Elevidys, or to chance alone,” they wrote.Marks took an opposite view, finding Sarepta’s secondary study findings “compelling.” He also argued that historical data suggests even a small benefit compared to a placebo in someone with Duchenne is “clinically meaningful.”"
Hope he takes this view with the DREAM-HF trial...
- Forums
- ASX - By Stock
- 2024 Here we go again.
"Notably, they rejected Sarepta’s arguments that Elevidys’...
-
-
- There are more pages in this discussion • 305 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.5¢ |
Change
-0.070(6.57%) |
Mkt cap ! $1.141B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | 99.5¢ | $3.980M | 3.944M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 56239 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 103125 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 5201 | 1.045 |
2 | 9462 | 1.040 |
11 | 15149 | 1.030 |
8 | 114199 | 1.020 |
5 | 50162 | 1.015 |
Price($) | Vol. | No. |
---|---|---|
0.600 | 39216 | 1 |
0.885 | 5186 | 1 |
0.920 | 245 | 1 |
0.930 | 49441 | 1 |
0.945 | 384 | 2 |
Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |